Last reviewed · How we verify
Adjuvanted pandemic influenza candidate vaccine
This vaccine stimulates the immune system to recognize and respond to pandemic influenza virus antigens, with an adjuvant component to enhance the immune response.
This vaccine stimulates the immune system to recognize and respond to pandemic influenza virus antigens, with an adjuvant component to enhance the immune response. Used for Pandemic influenza prevention in adults.
At a glance
| Generic name | Adjuvanted pandemic influenza candidate vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Adjuvanted inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated or recombinant influenza virus antigens combined with an adjuvant (likely AS04, containing aluminum hydroxide and MPL) that amplifies the body's innate and adaptive immune responses. This adjuvanted formulation is designed to provide enhanced immunogenicity and potentially broader or more durable protection against pandemic influenza strains compared to non-adjuvanted vaccines.
Approved indications
- Pandemic influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults (PHASE3)
- Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population (PHASE2)
- Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age (PHASE2)
- Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children (PHASE2)
- Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine (PHASE2)
- Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years (PHASE2)
- Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: